A role for metalloendopeptidases in the breakdown of the gut hormone, PYY 3-36

Endocrinology

Volumn 152, Issue 12, 2011, Pages 4630-4640

  Addison, Melisande L ^a   Minnion, James S ^a   Shillito, Joy C ^a   Suzuki, Keisuke ^a   Tan, Tricia M ^a   Field, Benjamin C T ^a   Germain Zito, Natacha ^a   Becker Pauly, Christoph ^a,b   Ghatei, Mohammad A ^a   Bloom, Stephen R ^a   Murphy, Kevin G ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINONIN; MEMBRANE METALLOENDOPEPTIDASE; MEPRIN BETA; PEPTIDE YY [3-36]; PHOSPHORAMIDON; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANOREXIA; ARTICLE; BIODEGRADATION; BODY WEIGHT; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; FOOD INTAKE; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; KIDNEY TUBULE EPITHELIUM; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; ENZYME INHIBITORS; GASTROINTESTINAL HORMONES; HALF-LIFE; KIDNEY; METALLOENDOPEPTIDASES; MICE; PEPTIDE YY; PROTEIN STABILITY; TIOPRONIN;

EID: 82355163432     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1195     Document Type: Article

References (46)

1. World Health Organization 2006 Obesity: preventing and managing to global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894:1-253
2. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath Jr CW 1999 Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 341:1097-1105 (Pubitemid 29466221)
3. Kopelman PG 2000 Obesity as a medical problem. Nature 404:635-643 (Pubitemid 30205068)
4. Tharakan G, Tan T, Bloom S 2011 Emerging therapies in the treatment of 'diabesity': beyond GLP-1. Trends Pharmacol Sci 32:8-15
5. Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, Alsaraf S, Amber V, Wynne K, Ghatei MA, Bloom SR 2010 PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 59:1635-1639
6. Murphy KG, Bloom SR 2006 Gut hormones and the regulation of energy homeostasis. Nature 444:854-859 (Pubitemid 46024992)
7. Nygaard R, Nielbo S, Schwartz TW, Poulsen FM 2006 The PP-fold solution structure of human polypeptide YY and human PYY3-36 as determined by NMR. Biochemistry 45:8350-8357 (Pubitemid 44036541)
8. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA, Bloom SR 2005 The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044:127-131 (Pubitemid 40616060)
9. Abbott CR, Small CJ, Kennedy AR, Neary NM, Sajedi A, Ghatei MA, Bloom SR 2005 Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res 1043:139-144 (Pubitemid 40603381)
10. Boey D, Lin S, Karl T, Baldock P, Lee N, Enriquez R, Couzens M, Slack K, Dallmann R, Sainsbury A, Herzog H 2006 Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 49:1360-1370
11. Koda S, Date Y, Murakami N, Shimbara T, Hanada T, Toshinai K, Niijima A, Furuya M, Inomata N, Osuye K, Nakazato M 2005 The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 146:2369-2375 (Pubitemid 40577525)
12. Neary MT, Batterham RL 2009 Peptide YY: food for thought. Physiol Behav 97:616-619
13. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR 2003 Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349:941-948 (Pubitemid 37064767)
14. Chelikani PK, Haver AC, Reidelberger RD 2007 Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 293:R39-R46 (Pubitemid 47092160)
15. Pittner RA, Moore CX, Bhavsar SP, Gedulin BR, Smith PA, Jodka CM, Parkes DG, Paterniti JR, Srivastava VP, Young AA 2004 Effects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 28:963-971 (Pubitemid 38998700)
16. Korner J, Bessler M, Cirilo LJ, Conwell IM, Daud A, Restuccia NL, Wardlaw SL 2005 Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 90:359-365 (Pubitemid 40116682)
17. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR 2006 Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243:108-114 (Pubitemid 43054062)
18. van den Hoek AM, Heijboer AC, Corssmit EP, Voshol PJ, Romijn JA, Havekes LM, Pijl H 2004 PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes 53:1949-1952 (Pubitemid 38970740)
19. van den Hoek AM, Heijboer AC, Voshol PJ, Havekes LM, Romijn JA, Corssmit EP, Pijl H 2007 Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am J Physiol Endocrinol Metab 292:E238-E245 (Pubitemid 46052946)
20. Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ 2006 PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 291:R367-R375 (Pubitemid 44035643)
21. le Roux CW, Borg CM, Murphy KG, Vincent RP, Ghatei MA, Bloom SR 2008 Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake. Ann Clin Biochem 45:93-95 (Pubitemid 351724622)
22. Sloth B, Holst JJ, Flint A, Gregersen NT, Astrup A 2007 Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 292:E1062-E1068 (Pubitemid 46536505)
23. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A 2004 Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084 (Pubitemid 38619835)
24. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG 2006 Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 7:367-374
25. Malm-Erjefält M, Bjørnsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, van Lier JJ, Zdravkovic M, Olsen AK 2010 Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 38:1944-1953
26. Medeiros MD, Turner AJ 1994 Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. Endocrinology 134:2088-2094 (Pubitemid 24142947)
27. Erdös EG, Skidgel RA 1989 Neutral endopeptidase24.11(enkephalinase) and related regulators of peptide hormones. FASEB J 3:145-151
28. Yamaguchi T, Fukase M, Kido H, Sugimoto T, Katunuma N, Chihara K 1994 Meprin is predominantly involved in parathyroid hormone degradation by the microvillar membranes of rat kidney. Life Sci 54:381-386 (Pubitemid 24049599)
29. Bertenshaw GP, Turk BE, Hubbard SJ, Matters GL, Bylander JE, Crisman JM, Cantley LC, Bond JS 2001 Marked differences between metalloproteases meprin A and B in substrate and peptide bond specificity. J Biol Chem 276:13248-13255
30. Sterchi EE, Stöcker W, Bond JS 2008 Meprins, membrane-bound and secreted astacin metalloproteinases. Mol Aspects Med 29:309-328
31. Kronenberg D, Bruns BC, Moali C, Vadon-Le Goff S, Sterchi EE, Traupe H, Böhm M, Hulmes DJ, Stöcker W, Becker-Pauly C 2010 Processing of procollagen III by meprins: new players in extracellular matrix assembly? J Invest Dermatol 130:2727-2735
32. Druce MR, Minnion JS, Field BC, Patel SR, Shillito JC, Tilby M, Beale KE, Murphy KG, Ghatei MA, Bloom SR 2009 Investigation of structure-activity relationships of oxyntomodulin (Oxm) using Oxm analogs. Endocrinology 150:1712-1722
33. Pankow K, Wang Y, Gembardt F, Krause E, Sun X, Krause G, Schultheiss HP, Siems WE, Walther T 2007 Successive action of meprinA and neprilysin catabolizes B-type natriuretic peptide. Circ Res 101:875-882 (Pubitemid 350287174)
34. Booth AG, Kenny AJ 1974 A rapid method for the preparation of microvilli from rabbit kidney. Biochem J 142:575-581
35. Day AL, Wick E, Jordan TH, Jaffray CE, Bunnett NW, Grady EF, Kirkwood KS 2005 Neutral endopeptidase determines the severity of pancreatitis-associated lung injury. J Surg Res 128:21-27 (Pubitemid 41188205)
36. Carmago S, Shah SV, Walker PD 2002 Meprin, a brush-border enzyme, plays an important role in hypoxic/ischemic acute renal tubular injury in rats. Kidney Int 61:959-966 (Pubitemid 34175464)
37. Parkinson JR, Dhillo WS, Small CJ, Chaudhri OB, Bewick GA, Pritchard I, Moore S, Ghatei MA, Bloom SR 2008 PYY3-36 injection in mice produces an acute anorexigenic effect followed by a delayed orexigenic effect not observed with other anorexigenic gut hormones. Am J Physiol Endocrinol Metab 294:E698-E708 (Pubitemid 351483594)
38. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR 1985 Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070-1077 (Pubitemid 16231572)
39. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR 2002 Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650-654
40. Medeiros MD, Turner AJ, Ljungqvist A, Folkers K 1991 Metabolic stability of the LHRH antgonist antide to cell-surface peptidases. Biochem Biophys Res Common 176:25-30
41. Xu Y, Lai LT, Gabrilove JL, Scheinberg DA 1998 Antitumor activity of actinonin in vitro and in vivo. Clin Cancer Res 4:171-176 (Pubitemid 28062892)
42. Plamboeck A, Holst JJ, Carr RD, Deacon CF 2005 Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48:1882-1890 (Pubitemid 41317844)
43. Hedrich J, Lottaz D, Meyer K, Yiallouros I, Jahnen-Dechent W, Stöcker W, Becker-Pauly C 2010 Fetuin-A and cystatin C are endogenous inhibitors of human meprin metalloproteases. Biochemistry 49:8599-8607
44. Kruse MN, Becker C, Lottaz D, Köhler D, Yiallouros I, Krell HW, Sterchi EE, Stöcker W 2004 Human meprin α and β homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. Biochem J 378:383-389 (Pubitemid 38367229)
45. Nadkarni PP, Costanzo RM, Sakagami M 2011 Pulmonary delivery of peptide yy for food intake suppression and reduced body weight gain in rats. Diabetes Obes Metab 13:408-417
46. Field BC, Chaudhri OB, Bloom SR 2010 Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol 6:444-453